DNA hypomethylating agents can restore RIPK3 expression in cancer cells, “rescuing” their necroptotic capacities and enhancing various beneficial effects of chemotherapy, including promotion of anti-tumor immunity [201]. Here, RIPK3 is linked to neoplasm.